Vaxart Issues Statement Regarding Proposed Merger With Aviragen

Published: 1/02/2018
Vaxart Issues Statement Regarding Proposed Merger With Aviragen
Source: WWW.BUSINESSWIRE.COM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc. today commented on the Company’s proposed merger with Aviragen Therapeutics, Inc. (NASDAQ:AVIR). The following is a statement from Wouter Latour, M.D., Chief Executive Officer of Vaxart, who will lead the combined company following completion of the transaction: We are thrilled with the prospects of combining forces with Aviragen. In addit

Read more
Related news
Comment